Citation: Mengchi Sun, Weiyue Ban, Hao Ling, Xiang Yu, Zhonggui He, Qikun Jiang, Jin Sun. Emerging nanomedicine and prodrug delivery strategies for the treatment of inflammatory bowel disease[J]. Chinese Chemical Letters, ;2022, 33(10): 4449-4460. doi: 10.1016/j.cclet.2022.03.061 shu

Emerging nanomedicine and prodrug delivery strategies for the treatment of inflammatory bowel disease

Mengchi Sun ^{a, 1} ,
Weiyue Ban ^{a, 1} ,
Hao Ling ^a ,
Xiang Yu ^b ,
Zhonggui He ^a ,
Qikun Jiang ^{a, *,} ,
Jin Sun ^{a, *,}

a.
Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang 110016, China
b.
Huzhou Central Hospital, Affiliated Huzhou Hospital, Zhejiang University School of Medicine, Affiliated Central Hospital Huzhou University, Huzhou 110016, China

jiangqikunlqq@163.com

sunjin@syphu.edu.cn

Received Date: 15 November 2021
Revised Date: 9 March 2022
Accepted Date: 15 March 2022
Available Online: 17 March 2022

Figures(5)

Inflammatory bowel disease (IBD) is a chronic and recurrent disease of the gastrointestinal tract, mainly including Crohn's disease (CD) and ulcerative colitis (UC). However, current approaches against IBD do not precisely deliver drugs to the inflammatory site, which leads to life-long medication and serious side effects that can adversely impact patients' adherence. It is necessary to construct optimal drug delivery systems (DDSs) that can target drugs to the region of inflammation, thereby improve therapeutic efficacy and reduce side effects. With the burgeoning development of nanotechnology-based nanomedicines (NMs) and prodrug strategy, remarkable progresses in the treatment of IBD have been made in recent years. Herein, the latest advances are outlined at the intersection of IBD treatment and nanotherapeutics as well as prodrug therapy. First, the pathophysiological microenvironment of inflammatory sites of IBD is introduced in order to rationally design potential NMs and prodrugs. Second, the necessity of NMs for the IBD therapy is elaborated, and the representative nanotherapeutics via passive targeted and active targeted NMs developed to treat the IBD are overviewed. Furthermore, the emerging prodrug-based therapeutics are summarized, including 5-aminosalicylic acid-, amino acid-, and carbohydrate-conjugated prodrugs. Finally, the design considerations and perspectives of these NMs and prodrugs-driven IBD therapeutics in the clinical translation are spotlighted.
1. [1]
  C. Mowat, A. Cole, A. Windsor, et al., Gut 60 (2011) 571. doi: 10.1136/gut.2010.224154
2. [2]
  R.J. Xavier, D.K. Podolsky, Nature 448 (2007) 427-434. doi: 10.1038/nature06005
3. [3]
  C. Polytarchou, A. Oikonomopoulos, S. Mahurkar, et al., Inflamm. Bowel Dis. 21 (2015) 2533-2539. doi: 10.1097/MIB.0000000000000547
4. [4]
  S.M. Barbalho, R.A. Goulart, G. Batista, Expert Rev. Gastroenterol. Hepatol. 13 (2019) 25-35. doi: 10.1080/17474124.2019.1543588
5. [5]
  Y. Lee, K. Sugihara, M.G. Gillilland, et al., Nat. Mater. 19 (2020) 118-126. doi: 10.1038/s41563-019-0462-9
6. [6]
  S.D. Saini, A.K. Waljee, P.D.R. Higgins, Clin. Gastroenterol. Hepatol. 10 (2012) 1143-1151. doi: 10.1016/j.cgh.2012.05.003
7. [7]
  P. Li, X. Yang, Y. Yang, et al., J. Control. Release 319 (2020) 87-103. doi: 10.1016/j.jconrel.2019.12.025
8. [8]
  R.B. Sartor, Gastroenterology 139 (2010) 1816-1819. doi: 10.1053/j.gastro.2010.10.036
9. [9]
  S. Zhou, B. Zhang, X. Liu, et al., J. Pharm. Sci. 98 (2009) 4756-4768. doi: 10.1002/jps.21790
10. [10]
  J. Hansen, A. Gulati, R. Sartor, Curr. Opin. Gastroenterol. 26 (2010) 564-571. doi: 10.1097/MOG.0b013e32833f1195
11. [11]
  J. Xu, Y. Zhang, J. Xu, et al., Biomaterials 216 (2019) 119247. doi: 10.1016/j.biomaterials.2019.119247
12. [12]
  J.N. Manda, M. Markovic, E. Zimmermann, et al., ChemMedChem 15 (2020) 1639-1644. doi: 10.1002/cmdc.202000317
13. [13]
  F. Sadeghi, A. Eidizade, S.F. Saremnejad Namini, et al., Iran. J. Basic Med. Sci. (2020) 781-787.
14. [14]
  B. Huang, Z. Chen, L. Geng, et al., Cell 179 (2019) 1160-1176.e1124. doi: 10.1016/j.cell.2019.10.027
15. [15]
  C.R.H. Hedin, S.R. Vavricka, A.J. Stagg, et al., J. Crohn Colitis 13 (2019) 541-554. doi: 10.1093/ecco-jcc/jjy191
16. [16]
  J. Bratten, M.P. Jones, Dig. Dis. 24 (2006) 252-259. doi: 10.1159/000092878
17. [17]
  S.G. Nugent, D. Kumar, D.S. Rampton, D.F. Evans, Gut 48 (2001) 571-577. doi: 10.1136/gut.48.4.571
18. [18]
  S. Hua, E. Marks, J.J. Schneider, S. Keely, Nanomed. Nanotechnol. Biol. Med. 11 (2015) 1117-1132. doi: 10.1016/j.nano.2015.02.018
19. [19]
  Y. Sasaki, R. Hada, H. Nakajima, S. Fukuda, A. Munakata, Am. J. Gastroenterol. 92 (1997) 114-118.
20. [20]
  J. Fallingborg, L.A. Christensen, B.A. Jacobsen, S.N. Rasmussen, Dig. Dis. Sci. 38 (1993) 1989-1993. doi: 10.1007/BF01297074
21. [21]
  E.L. McConnell, H.M. Fadda, A.W. Basit, Int. J. Pharm. 364 (2008) 213-226. doi: 10.1016/j.ijpharm.2008.05.012
22. [22]
  F.N. Christensen, S.S. Davis, J.G. Hardy, et al., J. Pharm. Pharmacol. 37 (1985) 91-95.
23. [23]
  S.V. Rana, S. Sharma, A. Malik, et al., Dig. Dis. Sci. 58 (2013) 2594-2598. doi: 10.1007/s10620-013-2694-x
24. [24]
  P.C. Kashyap, A. Marcobal, L.K. Ursell, et al., Gastroenterology 144 (2013) 967-977. doi: 10.1053/j.gastro.2013.01.047
25. [25]
  S.N. Reddy, G. Bazzocchi, S. Chan, et al., Gastroenterology 101 (1991) 1289-1297. doi: 10.1016/0016-5085(91)90079-Z
26. [26]
  V.R. Sinha, R. Kumria, Eur. J. Pharm. Sci. 18 (2003) 3-18. doi: 10.1016/S0928-0987(02)00221-X
27. [27]
  J. Hansen, A. Gulati, R.B. Sartor, Curr. Opin. Gastroenterol. 26 (2010) 564-571. doi: 10.1097/MOG.0b013e32833f1195
28. [28]
  J. Qin, R. Li, J. Raes, et al., Nature 464 (2010) 59-65. doi: 10.1038/nature08821
29. [29]
  J. Kountouras, D. Chatzopoulos, C. Zavos, Hepato-gastroenterology 48 (2001) 743-751.
30. [30]
  H. Zhu, Y.R. Li, Exp. Biol. Med. (Maywood, N.J.) 237 (2012) 474-480. doi: 10.1258/ebm.2011.011358
31. [31]
  L. Lih-Brody, S.R. Powell, K.P. Collier, et al., Dig. Dis. Sci. 41 (1996) 2078-2086. doi: 10.1007/BF02093613
32. [32]
  M. Eberlein, K.A. Scheibner, K.E. Black, et al., J. Inflamm. 5 (2008) 20. doi: 10.1186/1476-9255-5-20
33. [33]
  T. Zhang, J. Jiang, J. Liu, et al., Front. Med. 7 (2020) 207. doi: 10.3389/fmed.2020.00207
34. [34]
  Z. Wang, X.Y. Liang, X. Chang, et al., Molecules 24 (2019) 2832. doi: 10.3390/molecules24152832
35. [35]
  B.M. Fournier, C.A. Parkos, Mucosal Immunol. 5 (2012) 354-366. doi: 10.1038/mi.2012.24
36. [36]
  E. Kolaczkowska, P. Kubes, Nat. Rev. Immunol. 13 (2013) 159-175. doi: 10.1038/nri3399
37. [37]
  U.J. Sachs, C.L. Andrei-Selmer, A. Maniar, et al., J. Biol. Chem. 282 (2007) 23603-23612. doi: 10.1074/jbc.M701120200
38. [38]
  N. Hu, H. Mora-Jensen, K. Theilgaard-Mönch, et al., PloS One 9 (2014) e99671.
39. [39]
  G. Zhou, L. Yu, L. Fang, et al., Gut 67 (2018) 1052-1063. doi: 10.1136/gutjnl-2016-313535
40. [40]
  A. Mantovani, M.A Cassatella, C. Costantini, Nat. Rev. Immunol. 11 (2011) 519-531. doi: 10.1038/nri3024
41. [41]
  Y. Zheng, P.A. Valdez, D.M. Danilenko, et al., Nat. Med. 14 (2008) 282-289. doi: 10.1038/nm1720
42. [42]
  F. Chen, A. Cao, S. Yao, et al., J. Immunol. 196 (2016) 4390-4399. doi: 10.4049/jimmunol.1501541
43. [43]
  C.L. Zindl, J.F. Lai, Y.K. Lee, et al., Proc. Natl. Acad. Sci. U. S. A. 110 (2013) 12768-12773. doi: 10.1073/pnas.1300318110
44. [44]
  A.H. Gitter, K. Bendfeldt, JD. Schulzke, M. Fromm, FASEB J. 14 (2000) 1749-1753. doi: 10.1096/fj.99-0898com
45. [45]
  J.L. Madara, J. Stafford, J. Clin. Invest. 83 (1989) 724-727. doi: 10.1172/JCI113938
46. [46]
  A. Pawłowska-Kamieniak, P. Krawiec, Adv. Clin. Exp. Med. 30 (2021) 465-469. doi: 10.17219/acem/130356
47. [47]
  G. Bouma, W. Strober, Nat. Rev. Immunol. 3 (2003) 521-533. doi: 10.1038/nri1132
48. [48]
  Y. Meissner, A. Lamprecht, J. Pharm. Sci. 97 (2008) 2878-2891. doi: 10.1002/jps.21216
49. [49]
  S. Melgar, F. Shanahan, Autoimmunity 43 (2010) 463-477. doi: 10.3109/08916931003674709
50. [50]
  J.D. Schulzke, S. Ploeger, M. Amasheh, et al., Ann. N. Y. Acad. Sci. 1165 (2009) 294-300. doi: 10.1111/j.1749-6632.2009.04062.x
51. [51]
  W.C. Lim, Y. Wang, J.K. MacDonald, S. Hanauer, Cochrane Database Syst. Rev. 7 (2016) CD008870.
52. [52]
  D.C. Baumgart, W.J. Sandborn, Lancet 380 (2012) 1590-1605. doi: 10.1016/S0140-6736(12)60026-9
53. [53]
  J.F. Colombel, W.J. Sandborn, W. Reinisch, et al., N. Engl. J. Med. 362 (2010) 1383-1395. doi: 10.1056/NEJMoa0904492
54. [54]
  X. Wang, J. Yan, L. Wang, et al., Theranostics 10 (2020) 10808-10822. doi: 10.7150/thno.47601
55. [55]
  R. Panaccione, S. Ghosh, S. Middleton, et al., Gastroenterology 146 (2014) 392-400400.e393. doi: 10.1053/j.gastro.2013.10.052
56. [56]
  M. Neurath, Nat. Rev. Gastroenterol. Hepatol. 14 (2017) 688-688. doi: 10.1038/nrgastro.2017.138
57. [57]
  X.Y. Si, D. Merlin, B. Xiao, World J. Gastroenterol. 22 (2016) 7718-7726. doi: 10.3748/wjg.v22.i34.7718
58. [58]
  I.A. Brownlee, J. Knight, P.W. Dettmar, J.P. Pearson, Free Radic. Biol. Med. 43 (2007) 800-808. doi: 10.1016/j.freeradbiomed.2007.05.023
59. [59]
  L.B. Vong, T. Tomita, T. Yoshitomi, H. Matsui, Y. Nagasaki, Gastroenterology 143 (2012) 1027-1036 E3. doi: 10.1053/j.gastro.2012.06.043
60. [60]
  R.B. Sartor, Res. Immunol. 148 (1997) 567-576. doi: 10.1016/S0923-2494(98)80151-X
61. [61]
  L.B. Vong, T. Yoshitomi, K. Morikawa, et al., J. Gastroenterol. 49 (2014) 806-813. doi: 10.1007/s00535-013-0836-8
62. [62]
  R.P. Das, V.V. Gandhi, B.G. Singh, A. Kunwar, Curr. Pharm. Des. 25 (2019) 3034-3056. doi: 10.2174/1381612825666190830155319
63. [63]
  N. Bertrand, J. Wu, X. Xu, N. Kamaly, O.C. Farokhzad, Adv. Drug Deliv. Rev. 66 (2014) 2-25. doi: 10.1016/j.addr.2013.11.009
64. [64]
  J. Fang, W. Islam, H. Maeda, Adv. Drug Deliv. Rev. 157 (2020) 142-160. doi: 10.1016/j.addr.2020.06.005
65. [65]
  L.B. Vong, J. Mo, B. Abrahamsson, Y. Nagasaki, J. Control. Release 210 (2015) 19-25. doi: 10.1016/j.jconrel.2015.05.275
66. [66]
  B. Yang, J. Shi, Angew. Chem. Int. Ed. 59 (2020) 21829-21838. doi: 10.1002/anie.202004317
67. [67]
  M.R Nidhi, V. Kaur, et al., Saudi Pharm. J. 24 (2016) 458-472. doi: 10.1016/j.jsps.2014.10.001
68. [68]
  J. Varshosaz, A. Jaffarian Dehkordi, S. Golafshan, J. Microencapsul. 23 (2006) 329-339. doi: 10.1080/02652040600612405
69. [69]
  D. Pertuit, B. Moulari, T. Betz, et al., J. Control. Release 123 (2007) 211-218. doi: 10.1016/j.jconrel.2007.08.008
70. [70]
  C. Lautenschläger, C. Schmidt, D. Fischer, A. Stallmach, Adv. Drug. Deliv. Rev. 71 (2014) 58-76. doi: 10.1016/j.addr.2013.10.001
71. [71]
  P.D. Higgins, M. Skup, P.M. Mulani, J. Lin, J. Chao, Clin. Gastroenterol. Hepatol. 13 (2015) 316-321. doi: 10.1016/j.cgh.2014.07.017
72. [72]
  A. Lee, C. De Mei, M. Fereira, et al., Theranostics 7 (2017) 3653-3666. doi: 10.7150/thno.18183
73. [73]
  B. Frantz, E.C. Nordby, G. Bren, et al., EMBO J. 13 (1994) 861-870. doi: 10.1002/j.1460-2075.1994.tb06329.x
74. [74]
  F. Giron, A. Pastó, E. Tasciotti, B.P. Abraham, Inflamm. Bowel Dis. 25 (2019) 1871-1880. doi: 10.1093/ibd/izz205
75. [75]
  M.J. Carter, A.J. Lobo, S.P.L. Travis, Gut 53(Suppl. V) (2004) v1-v16.
76. [76]
  B.N. Cronstein, Rheum. Dis. Clin. N. Am. 23 (1997) 739-755. doi: 10.1016/S0889-857X(05)70358-6
77. [77]
  A.M. Helmy, M. Elsabahy, G.M. Soliman, M.A. Mahmoud, E.A. Ibrahim, Eur. J. Pharm. Sci. 109 (2017) 269-279. doi: 10.1016/j.ejps.2017.08.025
78. [78]
  C. Lin, T.C. Kuo, J.C. Lin, Y.C. Ho, F.L. Mi, Int. J. Biol. Macromol. 160 (2020) 558-570. doi: 10.1016/j.ijbiomac.2020.05.151
79. [79]
  W. Han, B. Xie, Y. Li, et al., Theranostics 9 (2019) 7458-7473. doi: 10.7150/thno.38081
80. [80]
  S. Lomholt, A. Mellemkjaer, M.B. Iversen, S.B. Pedersen, T.W. Kragstrup, BMC Rheumatol. 2 (2018) 27. doi: 10.1186/s41927-018-0036-5
81. [81]
  N. Nagai, S. Kubota, K. Tsubota, Y. Ozawa, J. Nutr. Biochem. 25 (2014) 1218-1225. doi: 10.1016/j.jnutbio.2014.05.015
82. [82]
  Y. Han, H. Jo, J.H. Cho, D.N. Dhanasekaran, Y.S. Song, Int. J. Mol. Sci. 20 (2019) 925. doi: 10.3390/ijms20040928
83. [83]
  J. Ma, M. Xue, S. Zhang, et al., Oncol. Rep. 41 (2019) 1051-1058.
84. [84]
  N. Iglesias, E. Galbis, M. Díaz-Blanco, et al., Int. J. Mol. Sci. 20 (2019) 398. doi: 10.3390/ijms20020398
85. [85]
  T.H.T. Nguyen, N.T. Trinh, H.N. Tran, et al., J. Control. Release 331 (2021) 515-524. doi: 10.1016/j.jconrel.2020.10.042
86. [86]
  A.E. Miroliaee, H. Esmaily, A. Vaziri-Bami, et al., Toxicol. Mech. Methods 21 (2011) 200-208. doi: 10.3109/15376516.2010.547887
87. [87]
  J. Fang, X. Wang, M. Lu, X. He, X. Yang, Int. J. Biol. Macromol. 114 (2018) 1257-1266. doi: 10.1016/j.ijbiomac.2018.04.022
88. [88]
  J. Zhang, S. Fan, Y. Mao, et al., Int. J. Biol. Macromol. 82 (2016) 505-513. doi: 10.1016/j.ijbiomac.2015.09.069
89. [89]
  C.H. Chen, Y.S. Lin, S.J. Wu, F.L. Mi, Carbohydr. Polym. 193 (2018) 163-172. doi: 10.1016/j.carbpol.2018.03.080
90. [90]
  L.C. Tsai, C.H. Chen, C.W. Lin, Y.C. Ho, F.L. Mi, Int. J. Biol. Macromol. 126 (2019) 141-150. doi: 10.1016/j.ijbiomac.2018.12.182
91. [91]
  M.C. Chen, F.L. Mi, Z.X. Liao, et al., Adv. Drug. Deliv. Rev. 65 (2013) 865-879. doi: 10.1016/j.addr.2012.10.010
92. [92]
  H.B.T. Moran, J.L. Turley, M. Andersson, E.C. Lavelle, Biomaterials 184 (2018) 1-9. doi: 10.1016/j.biomaterials.2018.08.054
93. [93]
  R. Xing, Y. Liu, K. Li, et al., Carbohydr. Polym. 157 (2017) 1288-1297. doi: 10.1016/j.carbpol.2016.11.001
94. [94]
  D. Wang, S. Jiang, F. Zhang, et al., Adv. Sci. 8 (2021) 2101562. doi: 10.1002/advs.202101562
95. [95]
  S. Jaracz, J. Chen, L.V. Kuznetsova, I. Ojima, Bioorg. Med. Chem. 13 (2005) 5043-5054. doi: 10.1016/j.bmc.2005.04.084
96. [96]
  C. Tacconi, S. Schwager, N. Cousin, et al., ACS Pharmacol. Transl. Sci. 2 (2019) 342-352. doi: 10.1021/acsptsci.9b00037
97. [97]
  N. Gaspar, G. Zambito, C. Löwik, L. Mezzanotte, Curr. Pharm. Des. 25 (2019) 1951-1961. doi: 10.2174/1381612825666190710114108
98. [98]
  O.H. Nielsen, J.B. Seidelin, L.K. Munck, G. Rogler, J. Int. Med. 270 (2011) 15-28. doi: 10.1111/j.1365-2796.2011.02344.x
99. [99]
  X. Cai, X. Wang, M. He, et al., Int. J. Pharm. 606 (2021) 120836. doi: 10.1016/j.ijpharm.2021.120836
100. [100]
  A. Rodriguez-Nogales, F. Algieri, L. De Matteis, et al., J. Int. Nanomed. 11 (2016) 5945-5958. doi: 10.2147/IJN.S116479
101. [101]
  J. Rayahin, J. Buhrman, Y. Zhang, T. Koh, R. Gemeinhart, ACS Biomater. Sci. Eng. 1 (2015) 481-493. doi: 10.1021/acsbiomaterials.5b00181
102. [102]
  L. Zheng, T.E. Riehl, W.F. Stenson, Gastroenterology 137 (2009) 2041-2051. doi: 10.1053/j.gastro.2009.08.055
103. [103]
  A.C. Petrey, C.A. Motte, Front. Immunol. 5 (2014) 101.
104. [104]
  J. Kapitulnik, Mol. Pharmacol. 66 (2004) 773. doi: 10.1124/mol.104.002832
105. [105]
  T.W. Sedlak, M. Saleh, D.S. Higginson, et al., Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 5171-5176. doi: 10.1073/pnas.0813132106
106. [106]
  H. Yin, K.J. Kauffman, D.G. Anderson, Nat. Rev. Drug Discov. 16 (2017) 387-399. doi: 10.1038/nrd.2016.280
107. [107]
  H. Yin, R.L. Kanasty, A.A. Eltoukhy, et al., Nat. Rev. Genet. 15 (2014) 541-555. doi: 10.1038/nrg3763
108. [108]
  A. Wittrup, J. Lieberman, Nat. Rev. Genet. 16 (2015) 543-552. doi: 10.1038/nrg3978
109. [109]
  B. Nagy, A. Farkas, E. Borbás, et al., AAPS PharmSciTech 20 (2018) 1.
110. [110]
  H. Li, Y. Yang, W. Hong, et al., Signal Transduct. Target. Ther. 5 (2020) 1. doi: 10.1038/s41392-019-0089-y
111. [111]
  S. Hua, E. Marks, J.J. Schneider, S. Keely, Nanomed. Nanotechnol. Biol. Med. 11 (2015) 1117-1132. doi: 10.1016/j.nano.2015.02.018
112. [112]
  W. Liu, Z. Dong, K. Liu, et al., Int. J. Pharm. 600 (2021) 120461. doi: 10.1016/j.ijpharm.2021.120461
113. [113]
  M.J. O'Neill, L. Bourre, S. Melgar, C.M. O'Driscoll, Drug Discov. Today 16 (2011) 203-218. doi: 10.1016/j.drudis.2011.01.003
114. [114]
  Q. Ren, S. Sun, X.D. Zhang, Nano Res. 14 (2021) 2535-2557. doi: 10.1007/s12274-021-3303-5
115. [115]
  H. Shi, X. Zhao, J. Gao, et al., Chin. Chem. Lett. 31 (2020) 3102-3106. doi: 10.1016/j.cclet.2020.03.039
116. [116]
  D.S. Wilson, G. Dalmasso, L. Wang, et al., Nat. Mater. 9 (2010) 923-928. doi: 10.1038/nmat2859
117. [117]
  R.C. Cheung, T.B. Ng, J.H. Wong, W.Y. Chan, Mar. Drugs 13 (2015) 5156-5186. doi: 10.3390/md13085156
118. [118]
  H.Q. Mao, K. Roy, V.L. Troung-Le, et al., J. Control. Release 70 (2001) 399-421. doi: 10.1016/S0168-3659(00)00361-8
119. [119]
  Y. Song, Y. Huang, F. Zhou, J. Ding, W. Zhou, Chin. Chem. Lett. 33 (2022) 597-612. doi: 10.1016/j.cclet.2021.08.090
120. [120]
  D. Chuan, T. Jin, R. Fan, L. Zhou, G. Guo, Adv. Colloid Interface Sci. 268 (2019) 25-38. doi: 10.1016/j.cis.2019.03.007
121. [121]
  N.G. Kotla, S. Rana, G. Sivaraman, et al., Adv. Drug Deliv. Rev. 146 (2019) 248-266. doi: 10.1016/j.addr.2018.06.021
122. [122]
  Z.R. Lu, J.G. Shiah, S. Sakuma, P. Kopečková, J. Kopeček, J. Control. Release 78 (2002) 165-173. doi: 10.1016/S0168-3659(01)00495-3
123. [123]
  A.K.A. Khan, J. Piris, S.C. Truelove, Lancet 310 (1977) 892-895. doi: 10.1016/S0140-6736(77)90831-5
124. [124]
  R.A. van Hogezand, Scand. J. Gastroenterol. 23 (1988) 17-20.
125. [125]
  R.P. Chan, D.J. Pope, A.P. Gilbert, et al., Dig. Dis. Sci. 28 (1983) 609-615. doi: 10.1007/BF01299921
126. [126]
  J. Nakamura, M. Kido, K. Nishida, H. Sasaki, Chem. Pharm. Bull. 40 (1992) 2572-2575. doi: 10.1248/cpb.40.2572
127. [127]
  J. Nakamura, K. Asai, K. Nishida, H. Sasaki, Chem. Pharm. Bull. 40 (1992) 2164-2168. doi: 10.1248/cpb.40.2164
128. [128]
  J. Nakamura, C. Tagami, K. Nishida, H. Sasaki, Chem. Pharm. Bull. 40 (1992) 547-549. doi: 10.1248/cpb.40.547
129. [129]
  A. Rubinstein, Crit. Rev. Ther. Drug Carr. Syst. 12 (1995) 101-149. doi: 10.1615/CritRevTherDrugCarrierSyst.v12.i2-3.10
130. [130]
  D.R. Friend, S. Phillips, A. McLeod, T.N. Tozer, J. Pharm. Pharmacol. 43 (1991) 353-355.
131. [131]
  D.R. Friend, G.W. Chang, J. Med. Chem. 27 (1984) 261-266. doi: 10.1021/jm00369a005
132. [132]
  D.R. Friend, G.W. Chang, J. Med. Chem. 28 (1985) 51-57. doi: 10.1021/jm00379a012
133. [133]
  B. Haeberlin, W. Rubas, HW. Nolen Iii, DR. Friend, Pharm. Res. 10 (1993) 1553-1562. doi: 10.1023/A:1018956232628
134. [134]
  H.W. Nolen, RN. Fedorak, DR. Friend, Biopharm. Drug Dispos. 18 (1997) 681-695. doi: 10.1002/(SICI)1099-081X(199711)18:8<681::AID-BDD56>3.0.CO;2-A
135. [135]
  E.J. Hehre, TW. Sery, J. Bacteriol. 63 (1952) 424-426. doi: 10.1128/jb.63.3.424-426.1952
136. [136]
  M. Inoue, M. Morikawa, M. Tsuboi, T. Yamada, M. Sugiura, Jpn. J. Pharmacol. 29 (1979) 17-25.
137. [137]
  A.D. McLeod, D.R. Friend, T.N. Tozer, J. Pharm. Sci. 83 (1994) 1284-1288. doi: 10.1002/jps.2600830919
138. [138]
  T. Loftsson, H. Friðriksdóttir, E. Stefánsson, et al., J. Pharm. Pharmacol. 46 (1994) 503-504.
139. [139]
  T. Irie, K. Uekama, Adv. Drug Deliv. Rev. 36 (1999) 101-123. doi: 10.1016/S0169-409X(98)00057-X
140. [140]
  V.J. Stella, R.A. Rajewski, Pharm. Res. 14 (1997) 556-567. doi: 10.1023/A:1012136608249
141. [141]
  A. Gerlóczy, A. Fónagy, P. Keresztes, L. Perlaky, J. Szejtli, Arzneimittel Forsch. 35 (1985) 1042-1047.
142. [142]
  J.H. Cummings, G.T. Macfarlane, Clin. Nutr. 16 (1997) 3-11.
143. [143]
  M.J. Zou, G. Cheng, H. Okamoto, et al., World J. Gastroenterol. 11 (2005) 7457-7460. doi: 10.3748/wjg.v11.i47.7457
144. [144]
  C. Lautenschläger, C. Schmidt, C.M. Lehr, D. Fischer, A. Stallmach, Eur. J. Pharm. Biopharm. 85 (2013) 578-586. doi: 10.1016/j.ejpb.2013.09.016
145. [145]
  C. Lautenschläger, C. Schmidt, K. Lange, A. Stallmach, Z. Gastroenterol. 53 (2015) 226-234. doi: 10.1055/s-0034-1398793
146. [146]
  H.S. Oz, J.L. Ebersole, Molecules 13 (2008) 452-474. doi: 10.3390/molecules13020452
1. [1]
  Shuheng Zhang , Yuanyuan Zhang , Wanyu Wang , Yuzhu Hu , Xinchuan Chen , Bilan Wang , Xiang Gao . A combination strategy of DOX and VEGFR-2 targeted inhibitor based on nanomicelle for enhancing lymphoma therapy. Chinese Chemical Letters, 2024, 35(12): 109658-. doi: 10.1016/j.cclet.2024.109658
2. [2]
  Jingting Wang , Yuanyuan Chen , Linlin Han , Shasha Xia , Xingyao Zhang , Peng Xue , Yuejun Kang , Jian Ming , Zhigang Xu . Microenvironment responsive pod-structured astaxanthin nanocarrier for ameliorating inflammatory bowel disease. Chinese Chemical Letters, 2024, 35(7): 109029-. doi: 10.1016/j.cclet.2023.109029
3. [3]
  Yunkang Tong , Haiqiao Huang , Haolan Li , Mingle Li , Wen Sun , Jianjun Du , Jiangli Fan , Lei Wang , Bin Liu , Xiaoqiang Chen , Xiaojun Peng . Cooperative bond scission by HRP/H₂O₂ for targeted prodrug activation. Chinese Chemical Letters, 2024, 35(12): 109663-. doi: 10.1016/j.cclet.2024.109663
4. [4]
  Yao-Hua Gu , Yu Chen , Qing Li , Neng-Bin Xie , Xue Xing , Jun Xiong , Min Hu , Tian-Zhou Li , Ke-Yu Yuan , Yu Liu , Tang Tang , Fan He , Bi-Feng Yuan . Metabolome profiling by widely-targeted metabolomics and biomarker panel selection using machine-learning for patients in different stages of chronic kidney disease. Chinese Chemical Letters, 2024, 35(11): 109627-. doi: 10.1016/j.cclet.2024.109627
5. [5]
  Wenjia Wang , Xingyue He , Xiaojie Wang , Tiantian Zhao , Osamu Muraoka , Genzoh Tanabe , Weijia Xie , Tianjiao Zhou , Lei Xing , Qingri Jin , Hulin Jiang . Glutathione-depleted cyclodextrin pseudo-polyrotaxane nanoparticles for anti-inflammatory oxaliplatin (Ⅳ) prodrug delivery and enhanced colorectal cancer therapy. Chinese Chemical Letters, 2024, 35(4): 108656-. doi: 10.1016/j.cclet.2023.108656
6. [6]
  Botao QU , Qian WANG , Xiaogang NING , Yuxin ZHOU , Ruiping ZHANG . Deeply penetrating photoacoustic imaging in tumor tissues based on dual-targeted melanin nanoparticle. Chinese Journal of Inorganic Chemistry, 2024, 40(5): 1025-1032. doi: 10.11862/CJIC.20230416
7. [7]
  Zhiyu Yu , Xiang Luo , Cheng Zhang , Xin Lu , Xiaohui Li , Pan Liao , Zhongqiu Liu , Rong Zhang , Shengtao Wang , Zhiqiang Yu , Guochao Liao . Mitochondria-targeted carrier-free nanoparticles based on dihydroartemisinin against hepatocellular carcinoma. Chinese Chemical Letters, 2024, 35(10): 109519-. doi: 10.1016/j.cclet.2024.109519
8. [8]
  Chuanfeng Fan , Jian Gao , Yingkai Gao , Xintong Yang , Gaoning Li , Xiaochun Wang , Fei Li , Jin Zhou , Haifeng Yu , Yi Huang , Jin Chen , Yingying Shan , Li Chen . A non-peptide-based chymotrypsin-targeted long-wavelength emission fluorescent probe with large Stokes shift and its application in bioimaging. Chinese Chemical Letters, 2024, 35(10): 109838-. doi: 10.1016/j.cclet.2024.109838
9. [9]
  A-Yang Wang , Sheng-Hua Zhou , Mao-Yin Ran , Xin-Tao Wu , Hua Lin , Qi-Long Zhu . Regulating the key performance parameters for Hg-based IR NLO chalcogenides via bandgap engineering strategy. Chinese Chemical Letters, 2024, 35(10): 109377-. doi: 10.1016/j.cclet.2023.109377
10. [10]
  Xilin Bai , Wei Deng , Jingjuan Wang , Ming Zhou . Enrichment-enhanced detection strategy in the optimized monitoring system of dopamine with carbon dots-based probe. Chinese Chemical Letters, 2025, 36(2): 109959-. doi: 10.1016/j.cclet.2024.109959
11. [11]
  Xiaoxiao Wang , Bolun Wang , Fenfen Ji , Jie Yan , Jiacheng Fang , Doudou Zhang , Ji Xu , Jing Ji , Xinran Hao , Hemi Luan , Yanjun Hong , Shulan Qiu , Min Li , Zhu Yang , Wenlan Liu , Xiaodong Cai , Zongwei Cai . Discovery of plasma biomarkers for Parkinson’s disease diagnoses based on metabolomics and lipidomics. Chinese Chemical Letters, 2024, 35(11): 109653-. doi: 10.1016/j.cclet.2024.109653
12. [12]
  Yujie Li , Ya-Nan Wang , Yin-Gen Luo , Hongcai Yang , Jinrui Ren , Xiao Li . Advances in synthetic biology-based drug delivery systems for disease treatment. Chinese Chemical Letters, 2024, 35(11): 109576-. doi: 10.1016/j.cclet.2024.109576
13. [13]
  Chao Zhang , Ai-Feng Liu , Shihui Li , Fang-Yuan Chen , Jun-Tao Zhang , Fang-Xing Zeng , Hui-Chuan Feng , Ping Wang , Wen-Chao Geng , Chuan-Rui Ma , Dong-Sheng Guo . A supramolecular formulation of icariin@sulfonatoazocalixarene for hypoxia-targeted osteoarthritis therapy. Chinese Chemical Letters, 2025, 36(1): 109752-. doi: 10.1016/j.cclet.2024.109752
14. [14]
  Huijie An , Chen Yang , Zhihui Jiang , Junjie Yuan , Zhongming Qiu , Longhao Chen , Xin Chen , Mutu Huang , Linlang Huang , Hongju Lin , Biao Cheng , Hongjiang Liu , Zhiqiang Yu . Luminescence-activated Pt(Ⅳ) prodrug for in situ triggerable cancer therapy. Chinese Chemical Letters, 2024, 35(7): 109134-. doi: 10.1016/j.cclet.2023.109134
15. [15]
  Linjie Ju , Zhongxi Huang , Qian Shen , Chan Fu , Shuanghe Li , Wenjie Duan , Chenfeng Xu , Weizhen An , Zhiqiang Zhai , Jifu Wei , Changmin Yu , Guoren Zhou . Glutathione depletion based Pt(Ⅳ) hybrid mesoporous organosilica delivery system to conquer cisplatin chemoresistance: A “one stone three birds” strategy. Chinese Chemical Letters, 2024, 35(10): 109450-. doi: 10.1016/j.cclet.2023.109450
16. [16]
  Zhe-Han Yang , Jie Yin , Lei Xin , Yuanfang Li , Yijie Huang , Ruo Yuan , Ying Zhuo . Research advancement of DNA-based intelligent hydrogels: Manufacture, characteristics, application of disease diagnosis and treatment. Chinese Chemical Letters, 2024, 35(10): 109558-. doi: 10.1016/j.cclet.2024.109558
17. [17]
  Kun-Heng Li , Hong-Yang Zhao , Dan-Dan Wang , Ming-Hui Qi , Zi-Jian Xu , Jia-Mi Li , Zhi-Li Zhang , Shi-Wen Huang . Mitochondria-targeted nano-AIEgens as a powerful inducer for evoking immunogenic cell death. Chinese Chemical Letters, 2024, 35(5): 108882-. doi: 10.1016/j.cclet.2023.108882
18. [18]
  Bin Fang , Jiaqi Yang , Limin Wang , Haoqin Li , Jiaying Guo , Jiaxin Zhang , Qingyuan Guo , Bo Peng , Kedi Liu , Miaomiao Xi , Hua Bai , Li Fu , Lin Li . A mitochondria-targeted H₂S-activatable fluorogenic probe for tracking hepatic ischemia-reperfusion injury. Chinese Chemical Letters, 2024, 35(6): 108913-. doi: 10.1016/j.cclet.2023.108913
19. [19]
  Hao Cai , Xiaoyan Wu , Lei Jiang , Feng Yu , Yuxiang Yang , Yan Li , Xian Zhang , Jian Liu , Zijian Li , Hong Bi . Lysosome-targeted carbon dots with a light-controlled nitric oxide releasing property for enhanced photodynamic therapy. Chinese Chemical Letters, 2024, 35(4): 108946-. doi: 10.1016/j.cclet.2023.108946
20. [20]
  Yiqiao Chen , Ao Liu , Biwen Yang , Zhenzhen Li , Binggang Ye , Zhouyi Guo , Zhiming Liu , Haolin Chen . Photoluminescence and photothermal conversion in boric acid derived carbon dots for targeted microbial theranostics. Chinese Chemical Letters, 2024, 35(9): 109295-. doi: 10.1016/j.cclet.2023.109295

Get Citation

PDF

XML

Metrics

PDF Downloads(3)
Abstract views(414)
HTML views(24)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142